Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study.
OBJECTIVE
The aim of the study was to investigate the relationship between methadone and buprenorphine treatment and self-reported symptoms in HIV-infected opioid dependent individuals receiving antiretroviral therapy (ART).


METHODS
Longitudinal study.


METHODS
The French MANIF2000 cohort was used to compare self-reported symptoms in buprenorphine and methadone patients also receiving ART.


METHODS
We selected individuals receiving ART and OAT (342 visits among 106 patients).


METHODS
Symptoms were self-reported using a list of 14 symptoms (e.g. nausea, fatigue, fever) perceived during the previous 4 weeks, including three painful symptoms (abdominal or muscular pain, headaches). A two-step Heckman approach enabled us to account for the non-random assignment of OAT: a probit model identified predictors of starting either buprenorphine or methadone. A Poisson regression based on generalized estimating equations (GEE) was then used to identify predictors of the number of symptoms while adjusting for the non-random assignment of OAT.


RESULTS
The median (interquartile range) number of symptoms was 4 (1-6) and 2 (1-6) among buprenorphine and methadone patients, respectively. After adjustment for non-random assignment of OAT type, depressive and opioid withdrawal symptoms, anxiolytics consumption and daily cannabis use, methadone patients were more likely to report a lower number of symptoms than those receiving buprenorphine.


CONCLUSIONS
Methadone patients on ART report fewer symptoms than buprenorphine patients on ART under current treatment conditions in France. Further experimental research is still needed to identify an OAT-ART strategy which would minimize the burden of self-reported symptoms and potential interactions, while assuring sustainability and response to both treatments.
Carrieri
M Patrizia
MP
NSERM, U912 (SE4S), Marseille, France Université Aix Marseille, IRD, UMR-S912, Marseille, France. pmcarrieri@aol.com
Roux
Perrine
P
Cohen
Julien
J
Ravaux
Isabelle
I
Dellamonica
Pierre
P
Protopopescu
Camelia
C
Spire
Bruno
B
Rosenblum
Andrew
A
D044966:Anti-Retroviral Agents / Q000009:adverse effects*; D001294:Attitude to Health; D002047:Buprenorphine / Q000627:therapeutic use*; D015331:Cohort Studies; D003863:Depression / Q000453:epidemiology; D005260:Female; D005602:France; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006297:Health Services Accessibility; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D055118:Medication Adherence; D008691:Methadone / Q000627:therapeutic use*; D058850:Opiate Substitution Treatment; D009293:Opioid-Related Disorders / Q000150:complications / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy / Q000453:epidemiology; D057566:Self Report; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000453:epidemiology; D016896:Treatment Outcome
D044966:Anti-Retroviral Agents; D002047:Buprenorphine; D008691:Methadone